A study of orthotopically implanted,patient-derived xenograft models of GBM demonstrated a high degree of variability inlactate labeling between tumors, which could be explained by differences in thelevels of the transcription factor c-Myc driving LDH-A expression and glycolyticactivity (17). The gene discussed is MYC; the disease is glioblastoma.